25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy
Purpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eye...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2014/306814 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850228446455660544 |
|---|---|
| author | Hiroshi Kunikata Naoko Aizawa Nobuo Fuse Toshiaki Abe Toru Nakazawa |
| author_facet | Hiroshi Kunikata Naoko Aizawa Nobuo Fuse Toshiaki Abe Toru Nakazawa |
| author_sort | Hiroshi Kunikata |
| collection | DOAJ |
| description | Purpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results. 25GMIVS was successfully used and led to improvement in visual acuity (P<0.01). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P=0.20) without an increase in the number of glaucoma medications (P=0.14). Conclusions. 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery. |
| format | Article |
| id | doaj-art-2b89a26b6ded4a1a995422ff9f2d6cd1 |
| institution | OA Journals |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-2b89a26b6ded4a1a995422ff9f2d6cd12025-08-20T02:04:31ZengWileyJournal of Ophthalmology2090-004X2090-00582014-01-01201410.1155/2014/30681430681425-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after TrabeculectomyHiroshi Kunikata0Naoko Aizawa1Nobuo Fuse2Toshiaki Abe3Toru Nakazawa4Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, JapanDepartment of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, JapanDepartment of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University Graduate School of Medicine, Sendai 980-8573, JapanDivision of Clinical Cell Therapy, Tohoku University Graduate School of Medicine, Sendai 980-8575, JapanDepartment of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, JapanPurpose. To determine the feasibility of using 25-gauge microincision vitrectomy surgery (25GMIVS) to treat vitreoretinal disease in glaucomatous eyes which have previously undergone trabeculectomy (TLE). Methods. A consecutive, interventional case series. We performed 25GMIVS in 15 glaucomatous eyes that had undergone TLE. Follow-up period was 11.5 months. Results. 25GMIVS was successfully used and led to improvement in visual acuity (P<0.01). We performed 25GMIVS for proliferative diabetic retinopathy with neovascular glaucoma in 53% of eyes (8 of 15). Although 3 eyes needed further TLE following 25GMIVS, final IOP was below 21 mmHg in all eyes except one eye (93%) and was comparable to pre-25GMIVS IOP (P=0.20) without an increase in the number of glaucoma medications (P=0.14). Conclusions. 25GMIVS is a feasible treatment for vitreoretinal disease in eyes with preexisting TLE, effective in both significantly improving BCVA and preserving the filtering bleb, while not excluding further glaucoma surgery.http://dx.doi.org/10.1155/2014/306814 |
| spellingShingle | Hiroshi Kunikata Naoko Aizawa Nobuo Fuse Toshiaki Abe Toru Nakazawa 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy Journal of Ophthalmology |
| title | 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy |
| title_full | 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy |
| title_fullStr | 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy |
| title_full_unstemmed | 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy |
| title_short | 25-Gauge Microincision Vitrectomy to Treat Vitreoretinal Disease in Glaucomatous Eyes after Trabeculectomy |
| title_sort | 25 gauge microincision vitrectomy to treat vitreoretinal disease in glaucomatous eyes after trabeculectomy |
| url | http://dx.doi.org/10.1155/2014/306814 |
| work_keys_str_mv | AT hiroshikunikata 25gaugemicroincisionvitrectomytotreatvitreoretinaldiseaseinglaucomatouseyesaftertrabeculectomy AT naokoaizawa 25gaugemicroincisionvitrectomytotreatvitreoretinaldiseaseinglaucomatouseyesaftertrabeculectomy AT nobuofuse 25gaugemicroincisionvitrectomytotreatvitreoretinaldiseaseinglaucomatouseyesaftertrabeculectomy AT toshiakiabe 25gaugemicroincisionvitrectomytotreatvitreoretinaldiseaseinglaucomatouseyesaftertrabeculectomy AT torunakazawa 25gaugemicroincisionvitrectomytotreatvitreoretinaldiseaseinglaucomatouseyesaftertrabeculectomy |